Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Breast cancer is the most common cancer in the UK. There are many types of breast cancer. Pertuzumab is a new treatment which is currently in development for one type of breast cancer called HER2-positive. It will be used to treat early stage cancer, and will be given after breast surgery. Pertuzumab is injected into the bloodstream and is given in addition to the current standard treatments of trastuzumab and chemotherapy.
Pertuzumab is currently being studied to see whether it improves survival and whether it is safe to use in people with breast cancer. If pertuzumab is licenced for use in the UK, it will provide a new treatment option for patients with one type of early breast cancer. Indexing Status Subject indexing assigned by CRD MeSH Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Humans; Trastuzumab Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000636 Date abstract record published 19/04/2016 |